Action Pharma completes EUR 5 million financing round to advance its lead project AP214
Action Pharma A/S has completed an internal financing round of EUR 5 million which is dedicated to advance the Company’s ongoing phase 2a studies, and the initiation of a phase 2b study, for AP214.
AP214 is being developed for the protection of acute kidney injury in patients undergoing cardiac surgery under cardiopulmonary bypass as its lead indication. Interim phase 2a efficacy and safety data are expected by the end of June 2010.
There following current shareholders of Action Pharma participated in the above financing round: Sunstone Capital, Global Life Science Ventures, SLS Invest and InnovationsKapital.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.